← ABBOTT LABORATORIES (ABT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ABBOTT LABORATORIES (ABT)
Pharmaceutical Preparations · market cap $180.5B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Abbott Laboratories is a diversified healthcare group. Per our data, 2024 revenue was 45% medical devices, 22% nutritionals, 20% diagnostics and 13% ex-US pharmaceuticals. The market cap is about $182.7B, and 2025 revenue was $44.3B with net income of $6.5B. Our pipeline table lists dozens of Phase 2/3 entries, but the only dated catalyst is an estimated 2026-12-15 Phase 2 readout for Modified FOLFIRINOX in locally advanced pancreatic adenocarcinoma. That is not a typical single-asset biotech setup.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Modified FOLFIRINOXimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABT-712 | Phase 3 | Chronic Low Back Pain |
| Zemplar Capsule | Phase 3 | Kidney Disease |
| ABT-263 | Phase 2 | Small Cell Lung Cancer |
| rosuvastatin calcium | Phase 3 | Mixed Dyslipidemia |
| Maxacalcitol | Phase 3 | Chronic Kidney Disease on Hemodialysis |
| ABT-639 | Phase 2 | Diabetic Neuropathic Pain |
| Hydrocodone/Acetaminophen on Extended Release | Phase 3 | Moderate to Severe Chronic, Non-malignant Pain |
| ABT-126 | Phase 2 | Cognitive Deficits in Schizophrenia |
| Extended-Release Hydrocodone/Acetaminophen | Phase 2 | Pain |
| Depakote ER | Phase 2 | Pediatric Epilepsy |
| Celsentri® | Phase 3 | HIV Infections |
| ABT-335 and simvastatin | Phase 3 | Dyslipidemia |
| OLE FD Adalimumab +/- MTX | Phase 3 | Arthritis, Juvenile Idiopathic |
| ABT-335 and atorvastatin calcium | Phase 3 | Dyslipidemia |
| SKP FlutiForm HFA pMDI | Phase 3 | Asthma |
| Levodopa carbidopa intestinal gel (LCIG) | Phase 3 | Advanced Parkinson's Disease |
| Modified FOLFIRINOX | Phase 2 | Locally Advanced Pancreatic Adenocarcinoma |
| DB adalimumab eow | Phase 3 | Crohn's Disease |
| Clarithromycin | Phase 3 | Acute Bacterial Sinusitis (ABS) |
| adalimumab (Humira) | Phase 3 | Ankylosing Spondylitis |
Price & technical context
3-month
+5.4%
6-month
+30.6%
12-month
-9.7%
52-wk range
$82.56–$130.59
vs 50-day MA
+9.2%
vs 200-day MA
+11.9%
Realized vol
28.1%
Max drawdown
-41.1%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.